Table 2.
Treatment strategies used for COVID-19 treatment in cancer patients
| References | Cancer type | Treatment strategies |
|---|---|---|
| 45 | Lung cancer | HCQ + azithromycin (n=8), HCQ + lopinavir/ritonavir (n=2), HCQ+ azithromycin + lopinavir/ritonavir (n=1), HCQ (n=1) |
| 85 | Breast cancer | Levofloxacin, piperacillin plus tazobactam combined with the antiviral combination of darunavir/cobicistat. To this combination, HCQ was added (n=1) |
| 197 | Multiple cancers | Remdesivir (n=1), Azithromycin (n=138), Tocilizumab (n=6), HCQ (n=150), Convalescent plasma (n=9), Systemic corticosteroids (n=117) |
| 47 | Solid and hematological malignancies | HCQ (n=89), Azithromycin (n=93), HCQ+ azithromycin (n=181) |
| 198 | Chronic lymphocytic leukemia | HCQ (n=108), Remdesivir (n=14), Lopinavir/Ritonavir (n=34, Tocilizumab (n=43), Intravenous immunoglobulin, (n=13.8), Corticosteroids (n=95), Azithromycin (n=53), Convalescent Plasma (n=10) |
| 199 | Pediatric cancers | Broad-spectrum antibiotics (n=5), HCQ (n=5), Lopinavir/Ritonavir (n=1), Oxygen support |
| 200 | Multiple cancers | Antibiotics (n=138), HCQ (n=107), Lopinavir/ritonavir (n=84), Corticosteroids (n=41), Corticosteroids (n=15), Tocilizumab (n=9) |
| 201 | Prostate cancer | Study included patients receiving ADT for cancer treatment (n=22) vs non-ADT group (n=36). ADT use was defined as hormones that lower the level of testosterone like Gonadotropin-releasing hormone (GnRH) analog or antagonist administered within three months and/or documented testosterone concentrations < 50 ng/dl within six months of COVID-19 diagnosis |
|
TI:
NCT04446429 |
Prostate cancer and benign prostatic hyperplasia | It is a clinical trial to explore the protective role of anti-androgen drugs dutasteride and proxalutamide in combination with ivermectin and azithromycin against COVID-19 |
n=number of patients, TI: Trial identifier (ClinicalTrials.gov Identifier)